This page shows the latest ImmunoGen news and features for those working in and with pharma, biotech and healthcare.
production of immunogens and also induced superior immune responses.
It combines two anti-cancer properties, trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1, which it licensed from biotech ImmunoGen.
The vaccine – called HTI – is an immunogen that is delivered into the body using viral vectors and aims to “re-educate” the immune system of patients so that they can control
Buys into ImmunoGen’s antibody-drug conjugate technology. Japanese pharma company Takeda has signed a deal potentially worth $230m with ImmunoGen for two anticancer targets. ... By partnering with ImmunoGen, we are able to leverage this important
Other anti-CD19 therapies in development include Sanofi/Immunogen's SAR3419 (phase II) and Seattle Genetics' SGN-CD19A (phase I), both of which are antibody-drug conjugates (ADCs) that combine an
threshold. Kadcyla is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin (trastuzumab) with ImmunoGen's DM1, a cytotoxic payload designed to boost its ability to kill tumour
More from news
Approximately 0 fully matching, plus 16 partially matching documents found.
250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.
Termination. As part of its ongoing re-prioritisation and trimming of its oncology pipeline and correspondingly downsizing and reorganising the R&D teams, Sanofi is terminating its agreement with ImmunoGen and
265. Immunogen / Takeda. Licence and collaboration option. Antibody-drug conjugate (ADC) technology to develop 2 anticancer products option on 3rd.
240.5. ImmunoGen / Novartis. Licence. ADC technology - extension of 2010 agreement.
This month ImmunoGen and Novartis announced a second licence under their 2010 agreement giving Novartis rights to the biotech's ADC technology to develop anticancer therapeutics to an undisclosed target. ... ImmunoGen could receive around $200m in
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.
Eric Guempel joins from Merck Serono. ImmunoGen has appointed Eric Guempel as the company's first VP of product strategy and programme management. ... Dr Charles Morris explained the creation of Guempel's new role. “Eric joins ImmunoGen in a new
David Johnston appointed chief financial officer. David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role. ... I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel
ImmunoGen said it also expects to advance a fourth compound into clinic studies in 2013. ... We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company.".
More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...